NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/05/2025
Voltar para busca
Dado oficial do USPTO
BESPAK
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BESPAK
ST13
US500000098420336Classe
5, 10, 40, 41, 42
Pedido
98420336
Registro
7782740
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
07/05/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 40, 41, 42
Data de depósito
26/02/2024
Data de registro
06/05/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/05/2025
Última transação
07/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
24
Localização do titular
Norfolk, GB
Examinador
GILLANI, MAHREEN
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Bespak Europe Limited
Representantes
Shannon Marie McKeon Dykema Gossett PLLC
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 40Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances for the treatment of infectiousviralbacterialmetabolicendocrineexocrinemuscularskeletalcardiovascularrespiratoryreproductivedigestiveexcretoryrenaloncologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinallymphaticintegumentarynervoushormonaldermatologicalpsychiatric and immunological related diseases and disorders; Pharmaceutical productsrespiratory drugs for treating respiratory diseases and asthma; respiratory vaccines
Classe 10
Drug delivery devices sold emptynasal inhalers for medical purposessold empty; pressurised metered dose inhalers (pMDI) for medical purposessold empty; nasal sprays for medical purposes; soft mist inhalers for medical purposessold empty; parts and fittings for all the aforesaid goods
Classe 40
Custom manufacture of medical devices for others; custom manufacture of medical devices to the order and specification of othersinhalers and drug delivery devices sold emptypharmaceuticals; custom manufacture of componentsparts and fittings for all the aforesaid products; management of product lifecycles for othersin the nature of custom manufacturing of medical devices to the order and specification of othersinhalers and drug delivery devices sold emptypharmaceuticals; custom manufacturing of injection molded parts for others; custom manufacture of active pharmaceutical ingredients for others; custom manufacture of pharmaceuticals for others
Classe 41
Provision of trainingteaching and educational services in the nature of workshopslecturesclasses and tutorialsall in the field of manufacturingengineeringchemistry and pharmaceuticals; training services in the field of injection molding manufacturing; advisoryconsultancy and information services relating to all the aforesaid
Classe 42
Research and development of medical apparatus and instruments for others; research and development of inhalers and design of prototyping services; metrology services; Research laboratory testing and analysis services in the field of prototypingmetrologymanufacturingengineeringchemistrymedical and pharmaceuticals; product quality testing services; quality control advisory services namely regulatory quality control advisory of pharmaceuticalsactive pharmaceuticals ingredientsmedical apparatus and instrumentsinhalers and drug delivery productspharma and medical related products and apparatus and management of product lifecycles for otherscontinuing scientific research in the nature of conducting and managing clinical trials and trials of medical apparatus and instrumentsinhalers and drug delivery productspharma and medical related products and apparatus; consulting services in the field of pharmaceutical research and development; consulting services in the field of drug delivery devices; advisoryconsultancy and information services relating to all the foresaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
06/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/03/2025
PUBO
PUBLISHED FOR OPPOSITION
18/03/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/03/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/01/2025
PUBO
PUBLISHED FOR OPPOSITION
28/01/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/01/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
02/01/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/01/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
02/01/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/11/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/09/2024
GNRT
NON-FINAL ACTION E-MAILED
16/09/2024
CNRT
NON-FINAL ACTION WRITTEN
16/09/2024
DOCK
ASSIGNED TO EXAMINER
13/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/07/2024
NWAP
NEW APPLICATION ENTERED
26/02/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BESPAK ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.